Takeda
LeaveRussia detail: Scaling Back
The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company, with partial American and British roots. It is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue.
Business in Russia
Japanese pharmaceutical giant Takeda is considering selling its Russian plant that produces, Ninlaro (ixazomib), a treatment for patients with multiple myeloma as well as other drugs.
Decision trail
Decision date 21/04/2023 · Reference ↗
Japan’s Takeda suspends new clinical trials in Russia and halts new investments in Russia, Supplies of drugs and clinical trials will continue. Takeda has taken further action to discontinue activities in Russia that are not essential to maintaining supply of medicines to patients and providing ongoing support to employees. This includes suspending all new investments, suspending advertising and promotion, not initiating new clinical trials and stopping enrollment of new patients in ongoing clinical trials. Despite statements about halting investments and transferring its manufacturing asset, Takeda continues to maintain an operational presence in Russia. The active Head of Legal Russia vacancy on the company’s official careers site indicates ongoing business operations requiring full legal and regulatory support.
Local stats (LeaveRussia)
Status history since 2022
- 03/08/2026 — scaling back · Imported from KSE LeaveRussia
Exposure profile
Full exposure profile is a Professional feature
Energy, transport and commodity exposure, supplier/customer links in the region and sanctioned-party proximity.
Upgrade to Professional